Media coverage about Vertex Pharmaceuticals (NASDAQ:VRTX) has been trending positive on Friday, Alpha One Sentiment Analysis reports. The research group, a division of Accern, rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.29 on Alpha One’s scale. Alpha One also gave news stories about the pharmaceutical company an impact score of 86 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Alpha One Sentiment Analysis’s rankings:
- SG Americas Securities LLC Sells 58389 Shares of Vertex Pharmaceuticals Incorporated (VRTX) (ibusinesslines.com)
- What Are Good Stocks to Invest In Now? (fool.com)
- Vertex Pharmaceuticals (VRTX) Earning Somewhat Favorable Press Coverage, Study Shows (campdesrecrues.com)
- Shares in Vertex Pharmaceuticals Incorporated (VRTX) Acquired by LMR Partners LLP (leisuretravelaid.com)
- Vertex Pharma (VRTX) Announces Nine Presentations of Data on ORKAMB and KALYDECO at ECFS Conference (streetinsider.com)
VRTX has been the topic of a number of recent research reports. Vetr upgraded Vertex Pharmaceuticals from a “sell” rating to a “buy” rating and set a $102.50 target price on the stock in a report on Tuesday, March 14th. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Monday, February 27th. Citigroup Inc. initiated coverage on Vertex Pharmaceuticals in a research report on Wednesday, March 1st. They set a “buy” rating and a $105.00 target price for the company. Finally, Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $143.00 price objective for the company in a report on Friday, March 31st. Nine investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus price target of $117.02.
Vertex Pharmaceuticals (VRTX) traded down 0.73% during mid-day trading on Friday, hitting $123.14. The company had a trading volume of 3,152,299 shares. Vertex Pharmaceuticals has a 12 month low of $71.46 and a 12 month high of $130.69. The firm has a market capitalization of $30.67 billion, a P/E ratio of 171.74 and a beta of 1.65. The company has a 50-day moving average price of $120.30 and a 200 day moving average price of $97.79.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.09. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. The firm had revenue of $714.72 million during the quarter, compared to analyst estimates of $692.64 million. During the same quarter in the previous year, the business earned $0.09 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 79.5% compared to the same quarter last year. Equities analysts forecast that Vertex Pharmaceuticals will post $1.66 EPS for the current fiscal year.
In related news, SVP Paul M. Silva sold 1,688 shares of the company’s stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $106.30, for a total value of $179,434.40. Following the transaction, the senior vice president now directly owns 21,759 shares in the company, valued at $2,312,981.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey M. Leiden sold 157,200 shares of the company’s stock in a transaction that occurred on Friday, April 28th. The shares were sold at an average price of $119.50, for a total value of $18,785,400.00. Following the completion of the transaction, the chief executive officer now owns 395,152 shares in the company, valued at $47,220,664. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 499,175 shares of company stock valued at $60,610,079. 1.90% of the stock is owned by company insiders.
WARNING: “Vertex Pharmaceuticals (VRTX) Earns Daily Media Sentiment Score of 0.29” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/06/16/vertex-pharmaceuticals-vrtx-given-daily-media-sentiment-score-of-0-29-updated-updated.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.